Product Development Pipeline - Roche GDC-6036/RG6330 is currently being evaluated for safety, PK, and Clinical trials evaluating the combination of CPIs with the KRASG12C inhibitor Roche has added RG6330 to the Ph. III B-FAST study investigating - Molecules in Motion: clinical trial updates and FDA filings -
Other KRAS-G12C inhibitors, GDC-6036 (NCT04449874), RG6330 KRAS-G12C allele-specific inhibitors exhibit promising efficacy in clinical trials Targeting KRAS in non-small-cell lung cancer: recent progress and
Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was designed to have high potency and selectivity. Methods: In a phase 1 study Development Pipeline_all disease areas|Chugai Pharmaceutical We will highlight the research program that led to the discovery and optimization of GDC-6036, which is currently in clinical development. Chemical Structure.
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS KRAS G12C inhibitor. Small molecule (Oral). Roche. RG7159. GlycArt - We started Phase Ib/II study for a KRAS G12C inhibitor RG6330 for Divarasib - Wikipedia
Description/ Summary: Divarasib (KRAS G12C, GDC-6036, RG6330) is an irreversible covalent inhibitor of the KRAS G12C mutant protein, resulting Divarasib (GDC-6036) is an experimental anticancer drug which acts as an inhibitor of the G12C mutant form of Kirsten rat sarcoma virus (KRAS),
Another KRASG12C Inhibitor in Ph. III, Bayer's Massive FXIa Ph. III 69 Data from an initial study suggested multiple mechanisms of resis- tance are possible with KRASG12C inhibitors, and no uni- versal or Divarasib adipate | GDC-6036 | RG6330 | KRAS G12C inhibitor
Small molecular inhibitors for KRAS-mutant cancers - PMC The treatment of advanced non-small cell lung cancer harboring Adagrasib is the second oral small molecule inhibitor of KRAS G12C to move into clinical trials. GDC-6036/RG6330, D-1553, JDQ443 and